Carcinomas News and Research

RSS
Scientists identify new biomarker linked to non-small cell lung cancer, head and neck cancers

Scientists identify new biomarker linked to non-small cell lung cancer, head and neck cancers

Scientists identify two markers that predict patient's resistance to radiation therapy for cancer

Scientists identify two markers that predict patient's resistance to radiation therapy for cancer

Novel feedback provides mechanistic link between chronic inflammation and carcinogenesis

Novel feedback provides mechanistic link between chronic inflammation and carcinogenesis

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Proteomics identifies possible RCC biomarkers

Proteomics identifies possible RCC biomarkers

Second common type of breast cancer appears to be good candidate for personalized treatment approach

Second common type of breast cancer appears to be good candidate for personalized treatment approach

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Driver mutations found in more than half of adenosquamous lung carcinomas

Driver mutations found in more than half of adenosquamous lung carcinomas

Two oncogenes work together to sustain population of cells in lung squamous cell carcinoma

Two oncogenes work together to sustain population of cells in lung squamous cell carcinoma

Findings expand treatment options for hormone-dependent breast cancer

Findings expand treatment options for hormone-dependent breast cancer

NIBIB-funded researchers develop microscopic technique to improve Mohs surgery

NIBIB-funded researchers develop microscopic technique to improve Mohs surgery

Foundation Medicine announces discovery of high incidence of ERBB2 alterations in MPUC patients

Foundation Medicine announces discovery of high incidence of ERBB2 alterations in MPUC patients

Researchers complete genomic analysis of cervical cancer in two patient populations

Researchers complete genomic analysis of cervical cancer in two patient populations

Blaze Bioscience to initiate first Phase 1 clinical study of BLZ-100 in patients with skin tumors

Blaze Bioscience to initiate first Phase 1 clinical study of BLZ-100 in patients with skin tumors

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Study helps explain why survival gap persists for African-Americans with head and neck cancer

Study helps explain why survival gap persists for African-Americans with head and neck cancer

Researchers reveal why some breast cancer cells are resistant to chemotherapy

Researchers reveal why some breast cancer cells are resistant to chemotherapy

UV radiation: A central factor behind Queensland’s record rates of Merkel cell carcinoma

UV radiation: A central factor behind Queensland’s record rates of Merkel cell carcinoma

Special issue on Helicobacter pylori provides new insights into diagnosis, prevention and treatment

Special issue on Helicobacter pylori provides new insights into diagnosis, prevention and treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.